Skip to main content
OpenTrials
Completed

NCT Number: NCT00960648

Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting

The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the everolimus-eluting stent (EES) and to determine clinical device and procedural success during commercial use of EES in the real world.

The investigators will compare EES (Xience/Promus, prospective arm) with sirolimus-eluting stent (SES, Cypher, retrospective arm).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Dankook University Hospital, Cheonan, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient agrees to participate in this study by signing the informed consent form.
  • Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.

Exclusion criteria

  • There are no exclusion criteria for this registry.

Treatment and study plan

Xience/Promus

Device

Active prospective registration of patients receiving everolimus-eluting stent

Other names: EES

Cypher

Device

Retrospective historical controls that received sirolimus-eluting stent

Other names: SES

Primary outcomes

  1. Major Adverse Cardiac Events (composite of cardiac death, non-fatal MI, target lesion revascularization)

    Time frame: 12 months

Secondary outcomes

  1. In-stent & In-segment Late Loss

    Time frame: 9 months

  2. Stent Thrombosis

    Time frame: 1 year

  3. Target Vessel Failure (composite of cardiac death, MI, and TVR)

    Time frame: 12 months

  4. Any death, cardiac death, MI, TLR, TVR

    Time frame: 1 year

  5. Composite rate of cardiac death and any MI

    Time frame: 1 year

  6. Composite rate of all death and any MI

    Time frame: 1 year

  7. Composite rate of all death, any MI (Q-wave and non Q-wave) and any repeat revascularization

    Time frame: 1 year

  8. Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy

    Time frame: 1 year

  9. Clinical device and procedural success

    Time frame: During the health care facility stay

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Collaborators

  • Abbott
  • Boston Scientific Corporation

Registry information

Official study title

EXCELLENT (Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing) Registry

Important dates

Study start
2008
Primary completion
2014
Study completion
2014
First posted
Aug 18, 2009
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.